Spaces · Joseph G. Pressey · Collections · Vascular & Bone Disorders
Collection
Collection by Dr. Joseph G. Pressey

Vascular & Bone Disorders

items total cited expert statements Updated Nov 17, 2026
Try
Intelligent Search· answers come only from this collection · not medical advice
Content of this collection items

PHACE syndrome is characterized by a variety of neurocutaneous and vascular anomalies that typically include segmental hemangiomas. Treatment of infantile hemangiomas with sirolimus in a patient with PHACE syndrome

Treatment of infantile hemangiomas with sirolimus in a patient with PHACE syndrome
Infantile hemangiomas (IHs) are common benign tumors of childhood. IHs often regress satisfactorily without intervention, but a subset of IHs may lead to functional or cosmetic morbidity necessitating therapy. PHACE syndrome is characterize
article · Nov 2026
Read →

Available therapies for Gorham-Stout disease are not uniformly effective and often carry substantial morbidity. Gorham-Stout Disease Successfully Treated With Sirolimus and Zoledronic Acid Therapy

Gorham-Stout Disease Successfully Treated With Sirolimus and Zoledronic Acid Therapy
Gorham-Stout disease is a life-threatening disorder often manifested by lymphatic malformation and osteolysis. Unfortunately, available therapies are not uniformly effective and often carry substantial morbidity. We report an 18-year-old ma
article · Nov 2026
Read →

Gorham-Stout Disease Successfully Treated With Sirolimus and Zoledronic Acid Therapy
Gorham-Stout disease is a life-threatening disorder often manifested by lymphatic malformation and osteolysis.
Established practice
Available therapies for Gorham-Stout disease are not uniformly effective and often carry substantial morbidity.
Established practice
An 18-year-old male with Gorham-Stout disease manifested by lytic rib lesions and intractable pleural effusion responded dramatically to combination therapy with sirolimus and zoledronic acid after failing interferon therapy.
Cites published research
The combination of sirolimus and zoledronic acid has demonstrated synergism in preclinical cancer models.
Cites published research
Treatment of infantile hemangiomas with sirolimus in a patient with PHACE syndrome
Infantile hemangiomas are common benign tumors of childhood.
Established practice
Infantile hemangiomas often regress satisfactorily without intervention.
Established practice
A subset of infantile hemangiomas may lead to functional or cosmetic morbidity necessitating therapy.
Established practice
PHACE syndrome is characterized by a variety of neurocutaneous and vascular anomalies that typically include segmental hemangiomas.
Established practice
Treatment with sirolimus provided benefit with regression of the cutaneous infantile hemangioma in a patient with PHACE syndrome who failed conventional first-line therapies.
Cites published research
Sirolimus is an inhibitor of the mammalian target of rapamycin (mTOR) pathway.
Established practice
GCMD Library — Curated collection · summaries prepared automatically from the recordings · educational content, not medical advice
Start the course
We remember your choice for this collection.
Follow this collection We'll email you when something new is added to Vascular & Bone Disorders — the new recordings themselves, with links. Nothing when nothing is added; every email has an unsubscribe link.